甘李药业：甘精胰岛素注射液获欧盟委员会上市许可

Core Viewpoint - The company and its wholly-owned subsidiary in Europe have received marketing authorization from the European Commission for its insulin injection product, Ondibta®, which is intended for diabetes treatment [1] Group 1: Product Development and Approval - The product Ondibta® has been granted marketing authorization in the EU, Iceland, Liechtenstein, and Norway [1] - The company has invested a total of 936 million yuan in research and development for this project as of September 30, 2025 [1] Group 2: Market Considerations - The expansion progress and sales scale of the product in the aforementioned regions are subject to uncertainties due to market demand, policies, exchange rates, and competition [1]